Top 5 Rare Kidney Disease Drug Developers
.png)
Published: January 2026
Kidney disorders are known to have a serious impact on the general kidney function, often lowering its ability to filter out waste and fluids from the blood, maintaining blood pressure, hemoglobin levels and electrolyte balance. Kidney disorders can either be short-term (acute kidney injury) or lifelong (chronic). There are several factors which contribute to an increased risk of developing kidney diseases, including genetic causes and underlying metabolic causes (diabetes, high blood pressure, aging and obesity), which when combined with other factors increase the risk of developing kidney diseases. Moreover, the rising incidence and prevalence of rare kidney diseases, with poor outcomes and high cost has led to an increased research activity in this domain.
Despite their relatively low prevalence, rare kidney diseases, including Immunoglobulin A nephropathy, lupus nephritis, focal segmental glomerular sclerosis, membranous nephropathy and C3 glomerulopathy, are believed to be major types of rare renal diseases. Diagnosis, management and treatment of such rare kidney diseases are complicated, especially when multi-system complications are present. Some of the challenges related to rare kidney diseases include small numbers of affected patients, insufficient model organisms, lack of biomarkers for monitoring disease progression, clinical heterogeneity, health policy constraints and need for complex care.
Rare kidney disorders are known to have a genetic basis that are frequently progressive, disabling and life-threatening. Additionally, the highly heterogeneous nature of rare kidney diseases has been a challenge for the identification of disease specific targets. In order to investigate the new pathophysiological pathways for the identification of human translatable biomarkers and increase the success rate in drug development, various technologies are being integrated, including next-generation sequencing , omics analysis and artificial intelligence, with the ability to probe the diseased organ directly
Roots Analysis has conducted an exhaustive study on Rare Kidney Diseases Market featuring the current market landscape and future opportunity for companies engaged in healthcare, over a span of next 10 years.
Top Five Rare Kidney Disease Drug Developers
1. Alexion Pharmaceuticals
2. Horizon Therapeutics
3. Hengrui Pharmaceuticals
4. Novartis
5. Sanofi
The figure below highlights the top five rare kidney disease drug developers:
Interested in exploring all ~110 players engaged in the development of drugs to treat rare kidney diseases, along with their recent initiatives?
Discover Below the Details on Top 5 Rare Kidney Disease Drug Developers
Let us dive deep into the details of the top 5 rare kidney disease drug developers. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
1. Alexion Pharmaceuticals
Company Overview
Alexion, part of AstraZeneca's Rare Disease unit, is a US-based company, specialized in developing innovative therapies for rare and devastating diseases. With expertise in complement biology, hematology, nephrology, neurology, and metabolic disorders, Alexion delivers life-changing medicines to patients in over 50 countries.
It is important to highlight that the company offers its services to various domains, including gene therapy, immunotherapy, and synthetic biology, through strategic research collaborations, technology licensing, and partnerships that accelerate breakthrough treatments for rare diseases worldwide.
Notably, In July 2021, Alexion Pharmaceuticals was acquired by AstraZeneca, in order to pioneer the discovery and development of drugs through the utilization of innovative complement-biology platform for rare kidney diseases.
Recent Developments
In March 2024, Alexion Pharmaceuticals sponsored the conference, named American KidneyFund (AKF) with the aim to spread awareness amongst public and motivate them to prioritize their kidney health and fight kidney disease.
To know more about the recent initiatives of Alexion and other rare kidney disease drug developers, access full report.
2. Horizon Therapeutics
Company Overview
Horizon is a research-intensive biopharmaceutical company specializing in the development and commercialization of life-changing therapies for people with rare, autoimmune, and inflammatory diseases. The company focuses on addressing critical unmet needs in rheumatology, nephrology, endocrinology, and neurology, delivering medicines that improve patient outcomes and quality of life.
It is worth highlighting that the company helps discover, develop, manufacture and deliver innovative medicines to help millions of patients. In October 2023, Horizon Therapeutics was acquired by Amgen, in order to expand its pipeline of clinical and preclinical programs for broader range of diseases.
Recent Developments
In March 2025, Amgen (parent company of Horizon Therapeutics) supported the virtual conference, Kidney Month 2025, organized by the American Kidney Fund (AKF) with the aim to educate the public and healthcare community regarding kidney disease.
To know more about the recent initiatives of Horizon Therapeutics and other rare kidney disease drug developers, access full report.
3. Hengrui Pharmaceuticals
Company Overview
Hengrui Pharmaceuticals is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience.
It is worth noting that the company has always prioritized scientific and technological innovation as its primary development strategy and has continued to increase its R&D investment. To date, Hengrui has invested more than RMB 50 billion in R&D, taking a lead in China's pharmaceutical industry.
Recent Developments
In December 2025, Hansoh Pharmaceutical entered into an agreement with Hengrui Pharmaceuticals for licensing SHR6508, a Phase III kidney drug.
To know more about the recent initiatives of Hengrui Pharmaceuticals and other rare kidney disease drug developers, access full report.
4. Novartis
Company Overview
Novartis is a healthcare company focused on discovery, development and manufacturing of generic pharmaceutical and eye care products. The company offers a wide range of drugs with the primary focus on various therapeutic areas such as oncological disorders, cardiovascular disorders, dermatological disorders, neurological disorders and various other disorders. The firm leverages innovative technologies and strategies to produce high-value medicines that have consistently improved the patient’s quality of life over the past two decades.
Recent Developments
In April 2025, Novartis received FDA approval for Vanrafia® (atrasentan), a selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
To know more about the recent initiatives of Novartis and other rare kidney disease drug
developers, access full report.
5. Sanofi
Company Overview
Sanofi specializes in research, development, manufacturing and marketing of pharmaceutical products. The company primarily focuses on developing solutions for therapeutic areas, such as oncology, immunology, neurology, inflammation and other rare diseases. It is worth mentioning that Sanofi's commitment to advance rare kidney disease drugs is reflected in their strategic partnerships, robust clinical trials, and investment in research and development. Notably, the firm aims to deliver medicines and vaccines for people across the globe; as per the company website, it has changed lives of around 2 million people in 40 low-income countries.
Recent Developments
In May 2024, the American Kidney Fund (AKF), in partnership with Sanofi, initiated an awareness campaign for the awareness of Fabry Disease. The campaign will include encouraging patients with chronic kidney disease (CKD) to promote diagnostic testing for Fabry disease to enable earlier intervention.
To know more about the recent initiatives of Sanofi and other rare kidney disease developers, access full report.
What About Other Rare Kidney Disease Drug Developers Around the World?
The above article features the top five rare kidney disease drug developers selected from a pool of around 110 drug developers that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources:
1. https://www.astrazeneca.com/media-centre/press-releases/2021/acquisition-of-alexion-completed.html#
5. https://longbridge.com/en/news/270917760?channel=WHAB0002